Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-a).
According to Perspective, patients are being selected for PSV359 targeted alpha particle therapy by SPECT imaging with PSV359.
In a statement, Markus Puhlmann, CMO of Perspective, commented, “Dosing the first patient in the second cohort marks an important step in advancing PSV359 for cancers expressing FAP-a. FAP-a is found in a wide range of epithelial malignancies, including pancreatic cancer, colorectal cancer, and many sarcomas. Because of its multi-factorial biologic effects within the tumor microenvironment, it contributes to disease progression and negatively affects treatment response. These characteristics highlight the broad potential of PSV359 across multiple solid tumors. This study is helping us determine the optimal dose and indications to move forward, either as a monotherapy or in future combination strategies.”
